Kantonsspital St.Gallen

SOS AMI Selatogrel

Micha T. Maeder, Susanne Vetsch & Karin Fink

abstract Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction
type of project clinical studies
status ongoing - recruiting phase
start of project 2022
end of project 2026
study design prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group, Phase 3 study
responsible person Prof. Micha Maeder